Journal
CANCER RESEARCH
Volume 82, Issue 14, Pages 2538-2551Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-21-2072
Keywords
-
Categories
Funding
- National Medical Research Council [NMRC/STaR/0026/2015, MOH-000967-00, OFLCG18May-0003]
- A*ccelerate GAP fund [ETPL/15-R15 GAP-0021]
- MOE tier 2 grant [MOE2017-T2-1-105]
- NMRC CS-IRG grant [NMRC/CIRG/1481/2017]
- SCISSOR (A*STAR IAF-PP) [H18/01/a0/020]
- Cancer Science Institute of Singapore, NUS, under the National Research Foundation Singapore
- Singapore Ministry of Education under its Research Centers of Excellence initiative
- Duke-NUS Medical School
- St. Baldrick's Foundation Research Award
- National Medical Research Council (NMRC) Fellowship, Singapore
- RNA Biology Center at the Cancer Science Institute of Singapore, NUS under the Singapore Ministry of Education Academic Research Fund Tier 3 [MOE2014-T3-1-006]
- National Research Foundation Singapore
Ask authors/readers for more resources
Mutations in the MSH2 gene are causative in gastric cancer, and MSH2 has a novel epigenomic function in regulating gene expression. MSH2 binds to tumor-associated superenhancers in early-stage gastric cancer, playing a role in chromatin rewiring and cell adhesion pathway expression. Loss of MSH2 in advanced gastric cancer leads to deficient cell adhesion pathway expression and enhanced tumorigenesis. Additionally, MSH2-deficient gastric cancer cells show addiction to BET inhibition.
Mutations in the DNA mismatch repair gene MSH2 are causative discovered that besides its well-established role in DNA repair, MSH2 exerts a novel epigenomic function in gastric cancer. Unbiased CRISPR-based mass spectrometry combined with genomewide CRISPR functional screening revealed that in early-stage but rather is associated specifically with tumor-associated superenhancers controlling the expression of cell adhesion genes. At these loci, MSH2 genomic binding was required for chromatin rewiring, de novo enhancer-promoter interactions, maintenance of histone acetylation levels, and regulation of cell adhesion pathway expression. The chromatin function of MSH2 was independent of its DNA repair catalytic activity but required MSH6, another DNA repair gene, and recruitment to gene loci by the SWI/SNF chromatin remodeler SMARCA4/BRG1. Loss of MSH2 in advanced gastric cancers was accompanied by deficient cell adhesion pathway expression, epithelial-mesenchymal transition, and enhanced tumorigenesis in vitro and in vivo. However, MSH2-deficient gastric cancers also displayed addiction to BAZ1B, a bromodomain- containing family member, and consequent synthetic lethality to bromodomain and extraterminal motif (BET) inhibition. Our results reveal a role for MSH2 in gastric cancer epigenomic regu- lation and identify BET inhibition as a potential therapy in MSH2- deficient gastric malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available